Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective
for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have
elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3).
The following recruitment strategies will be employed towards identifying healthy subjects
with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels:
-Pre-screening:
- first degree relatives of patients with rheumatoid arthritis (RA);
- subjects at health-fairs; and
- identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory
arthritis in rheumatology clinics.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)